Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus AR-targeted therapy in mCRPC
NCT02924766Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of niraparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Recommended Phase 2 Dose up to 56 days and Incidence and Severity of Adverse Events. Started Oct 2016; status: completed.
02
Drugs
niraparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02924766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924766.